Cardiovascular effects of the DPP-4 inhibitors

Diabetes & Vascular Disease Research : Official Journal of the International Society of Diabetes and Vascular Disease
Tessey Jose, Silvio E Inzucchi

Abstract

Type 2 Diabetes continues to rise in prevalence throughout the globe, and cardiovascular diseases remain the most common cause of morbidity and mortality among patients. Dipeptidyl-peptidase-4 (DPP-4) inhibitors are a newer class of oral anti-hyperglycemic agents whose effect is mediated through the incretin hormones, GLP-1 and GIP. In this review, we discuss the incretin system, DPP-4 inhibitors and their mechanism of action and, principally, the potential impact of DPP-4 inhibition on the cardiovascular system. Some pre-clinical data, small mechanistic studies and post-hoc analyses of randomized clinical trials suggest a possible beneficial effect on cardiovascular risk. However, the relationship between DPP-4 inhibition and actual cardiovascular outcomes remains unknown. We therefore also review ongoing large, randomized clinical trials examining this very question.

References

Oct 1, 1964·The Journal of Clinical Endocrinology and Metabolism·H ELRICKY ARAI
Dec 13, 2006·Diabetes & Vascular Disease Research : Official Journal of the International Society of Diabetes and Vascular Disease·Brian D GreenClifford J Bailey
Jul 12, 2007·JAMA : the Journal of the American Medical Association·Renee E AmoriAnastassios G Pittas
Jun 10, 2008·The New England Journal of Medicine·Anushka PatelFlorence Travert
Jun 10, 2008·The New England Journal of Medicine·UNKNOWN Action to Control Cardiovascular Risk in Diabetes Study GroupWilliam T Friedewald
Dec 18, 2008·The Journal of Clinical Endocrinology and Metabolism·Michael BoschmannJens Jordan
Dec 19, 2008·The New England Journal of Medicine·William DuckworthUNKNOWN VADT Investigators
Oct 23, 2009·Diabetes·Erik ArnerPeter Arner
Nov 18, 2010·American Journal of Physiology. Endocrinology and Metabolism·A D DobrianJ L Nadler
Jan 14, 2011·Diabetes Care·UNKNOWN American Diabetes Association
Mar 15, 2011·Vascular Pharmacology·Zubair ShahSanjay Rajagopalan
Jun 15, 2011·Vascular Pharmacology·Gian Paolo Fadini, Angelo Avogaro

❮ Previous
Next ❯

Citations

Sep 3, 2013·The New England Journal of Medicine·William B WhiteUNKNOWN EXAMINE Investigators
Nov 6, 2012·Journal of Nutrition and Metabolism·Dominique Xavier Brown, Marc Evans
May 28, 2013·Journal of Diabetes Research·Pegah Yousefzadeh, Xiangbing Wang
Jul 16, 2013·Journal of Diabetes Research·L Pala, C M Rotella
Sep 27, 2013·Drug Design, Development and Therapy·Annalisa CapuanoKatherine Esposito
Oct 2, 2012·Journal of Clinical Medicine Research·Akira KubotaIkuro Matsuba
Feb 14, 2014·Metabolic Syndrome and Related Disorders·Ishwarlal Jialal, Sandeep Dhindsa
Jan 7, 2014·Current Diabetes Reports·Sandeep Dhindsa, Ishwarlal Jialal
Apr 30, 2014·Reviews in Endocrine & Metabolic Disorders·Vladimer DarsaliaCesare Patrone
Jun 7, 2014·Biochimica Et Biophysica Acta·Luc RochetteCatherine Vergely
Jul 6, 2014·Heart, Lung & Circulation·Dilshani JayawardeneRichard J MacIsaac
Jun 4, 2013·Expert Opinion on Emerging Drugs·Avivit Cahn, Itamar Raz
Apr 22, 2014·Expert Opinion on Drug Metabolism & Toxicology·Theodosios D FilippatosMoses S Elisaf
Sep 29, 2015·Trends in Cardiovascular Medicine·Sanam Lathief, Silvio E Inzucchi
Jan 23, 2016·Clinical Pharmacokinetics·Puneet GaitondeStephan Schmidt
Oct 16, 2015·International Journal of Cardiology·Liberata SportielloAnnalisa Capuano
Nov 5, 2014·International Journal of Clinical Practice·M E RotzT F Thomas
Sep 18, 2013·European Journal of Pharmacology·Guanglei ChangDongying Zhang
Jun 16, 2015·Journal of Diabetes Research·Jixin ZhongSanjay Rajagopalan
Feb 12, 2013·Atherosclerosis·Ishwarlal Jialal, Mandeep Bajaj
Jun 9, 2016·Expert Opinion on Drug Safety·Lisa M YounkStephen N Davis
Jan 1, 2013·Expert Review of Endocrinology & Metabolism·Thomas Forst, Andreas Pfützner
Jun 16, 2014·American Journal of Physiology. Heart and Circulatory Physiology·Annayya R AroorVincent G DeMarco
Nov 20, 2012·Current Opinion in Lipidology·Suat Simsek, Bastiaan E de Galan
Jan 1, 2019·Journal of Diabetes Research·Mariana Nogueira CoutinhoMaria Eugênia Fernandes Canziani
Jul 3, 2013·Current Cardiology Reports·B SolunD Dicker
Jan 9, 2013·Nature Reviews. Cardiology·André J Scheen
Dec 10, 2020·Journal of Cellular and Molecular Medicine·Ilona CuijpersStephane Heymans

❮ Previous
Next ❯

Methods Mentioned

BETA
glycosylation

Software Mentioned

TECOS

Related Concepts

Related Feeds

Cardiovascular Biology of GLP-1

Glucagon-like peptide 1 (GLP-1) plays a role in glucose metabolism, energy homeostasis, and inflammation suppression. GLP-1 receptor signaling has been shown to impact cardiovascular function. This feed focuses on the role of GLP-1 and GLP-1 receptor agonists on cardiovascular biology.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.